ETIDRON ® - Ethidronic acid

ETIDRON ® is a drug based on sodium etidronate

THERAPEUTIC GROUP: Drugs affecting bone metabolism - Bisphosphonates

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ETIDRON ® - Ethidronic acid

ETIDRON ® is used in the treatment of the deforming osteite known as Rage of Paget.

Mechanism of action ETIDRON ® - Ethidronic acid

Ethidronic acid, the active ingredient of ETIDRON ® is a drug commonly used in the treatment of Paget's disease, a disease characterized by an altered bone turnover responsible for significant bone deformities, joint stiffness and in the most severe cases of neurological symptoms.

The therapeutic efficacy of this molecule is to correlate with its ability to settle at the bone level, inhibiting the reabsorption / neodeposition processes through the modulation of osteoclastic activity exerted through the control of gene expression.

The reduction of some markers such as alkaline phosphatase, following the intake of etidronic acid, is evidence of the therapeutic activity of ETIDRON ®

Studies carried out and clinical efficacy

1. THE BIPOSPHONATES IN THE MALLATIA OF PAGET

Study that reaffirms the importance of the use of bisphosphonates in the treatment of Paget's bone disease, and in the progressive improvement of the symptoms and blood concentrations of the various markers.

2. DENTAL CARE IN PATIENTS SUBJECTED TO THERAPY WITH BIPHOSPHONATES

Interesting case report that demonstrates the first successful case of fixed dental prostheses successfully implanted in the jaw of patients suffering from Paget's disease and undergoing bisphosphonate therapy.

3. OSTEOPOROSIS AND MULTIPLE VERTEBRAL FRACTURES IN PREGNANCY

Study demonstrating how drug therapy, epidural injection and a specific rehabilitation program can be valuable in the treatment of multiple vertebral crush fractures observed in women suffering from osteoporosis.

Method of use and dosage

ETIDRON ®

300 mg capsules of etidronic acid:

Paget's bone disease therapy involves taking about 300 - 600 mg per day of etidronic acid for at least six months.

In order to optimize the intestinal absorption of this molecule it would be ideal to prefer taking it on an empty stomach.

The optimal dosage must be defined by the physician based on the physio-pathological characteristics of the patient.

Warnings ETIDRON ® - Ethidronic acid

The use of ETIDRON ® must be preceded by a careful medical examination to assess the possible presence of conditions potentially incompatible with the intake of etidronic acid.

The increased risk of osteonecrosis of the jaw in patients receiving ETIDRON ® should be seriously considered before any dental treatment.

All patients undergoing etidronic acid therapy should be supervised by a doctor to avoid the occurrence of side effects.

ETIDRON ® contains lactose, therefore its use is not indicated in patients with lactase enzyme deficiency, galactose intolerance or glucose-galactose malabsorption syndrome.

PREGNANCY AND BREASTFEEDING

The absence of studies concerning the safety of etidronic acid on fetal health, when taken during pregnancy, allows extending the contraindications to the use of this drug also for the entire gestation period and the subsequent stage of lactation.

Interactions

At the moment active ingredients capable of interfering with the biological activity of etidronic acid are not known.

However, in order to optimize the intestinal absorption of this active ingredient it would be advisable to avoid the contextual intake of foods, drinks and drugs, especially calcium-based.

Contraindications ETIDRON ® - Ethidronic acid

ETIDRON ® is contraindicated in case of renal insufficiency and hypersensitivity to the active substance or to one of its excipients.

Undesirable effects - Side effects

Administration of ETIDRON ® could lead to the appearance of nausea, diarrhea, constipation, abdominal pain and bone pain.

Very rarely, clinically more relevant adverse reactions have been observed, such as allergic dermatological and respiratory reactions and neurological disorders such as headache, paresthesia and peripheral neuropathies.